Delivery Order SPE2DB20D1100-SPE2DB25FE1B9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) valued at $10,662.57. This firm fixed price delivery order, with an ultimate completion date of September 9, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 29, 2025, for the supply of Tagrisso 80 mg tablets (30-count packaging) with a ceiling value of $10,662.57 under a firm fixed-price contract. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of May 20, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) valued at $10,662.57 under a firm fixed price contract. This delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX and valued at $999,999,999.00 through December 2026), represents a competitive, non-set-aside award with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) valued at $21,325.14 under a firm fixed-price contract. This non-set-aside award represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Tagrisso 80 mg tablets (30-count packages) valued at $10,662.57 under a Firm Fixed Price contract type. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $21,325.14 and an ultimate completion date of September 30, 2025. This non-set-aside competitive award represents a child delivery order placed against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, PA, was awarded a delivery order valued at $10,662.57 by the Defense Logistics Agency (DLA) on April 21, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price, non-competitive delivery order is scheduled for completion by May 12, 2025, and represents a continuation of the company's extensive pharmaceutical supply relationship with the federal government. The award was...
- This delivery order, awarded on August 7, 2025, to AmerisourceBergen Drug Corp represents a $10,662.57 firm fixed-price contract for the supply of Tagrisso 80 mg tablets (30-count units) to the Defense Logistics Agency (DLA), a Defense Department component. The contract is competitively awarded with no set-aside designation and carries an ultimate completion date of August 28, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this...
- The Defense Logistics Agency awarded a $10,662.57 delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Tagrisso 80 mg tablets (30-count packages). This firm fixed-price contract, with an ultimate completion date of July 10, 2025, represents a competitively awarded, non-set-aside procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract value of $21,325.14. This non-set-aside delivery order utilizes firm fixed pricing and is scheduled for completion by September 30, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement and has established...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1B9Delivery Order
This delivery order, awarded on August 15, 2025, provides for the supply of Tagrisso 80 mg tablets (30-count units) to the Defense Logistics Agency (DLA) Medical Supply Chain through AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania. The order has a ceiling value of $10,662.57 and is structured as a firm fixed-price contract with an ultimate completion date of September 8, 2025. The award utilizes no set-aside designation and was competitively awarded to the prime contractor. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables comprehensive global pharmaceutical support for military healthcare programs. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting the Defense Health Agency and military healthcare systems. The company's extensive federal contract portfolio encompasses a wide range of pharmaceutical products, medical supplies, brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains. As a major healthcare solutions provider with significant capacity to fulfill federal medical supply requirements, AmerisourceBergen maintains its position as a key vendor under the DLA's pharmaceutical procurement strategy, with ongoing plans for the Pharmaceutical Prime Vendor Global Program Generation V to potentially involve multiple regional contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 8/15/25 |